Table 3.
Predicted eGFR change from baseline in patients on tenofovir-containing ART from two South African clinics
| Change from baseline (mL/min) Mean (95% CI) | 3 months | 6 months | 12 months | 24 months |
|---|---|---|---|---|
| MDRD | ‒0.3 (‒0.4 to ‒0.2) | ‒0.7 (‒0.8 to ‒0.5) | ‒1.3 (‒1.7 to ‒1.0) | ‒2.6 (‒3.3 to ‒1.9) |
| n1 | 9 295 | 5 234 | 5 537 | 2 486 |
| CKD-EPI | ‒0.3 (‒0.3 to ‒0.2) | ‒0.5 (‒0.6 to ‒0.4) | ‒1.0 (‒1.2 to ‒0.8) | ‒2.0 (‒2.5 to ‒1.6) |
| n1 | 9 295 | 5 234 | 5 537 | 2 486 |
| Cockcroft-Gault | 1.0 (0.9 to 1.1) | 2.0 (1.8 to 2.2) | 4.0 (3.5 to 4.4) | 8.0 (7.1 to 8.9) |
| n1 | 7 405 | 3 165 | 4 446 | 1 632 |
CI: confidence interval; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal Disease.
1. Patients who were on tenofovir at the relevant time point, and had at least one eGFR value available within 0.5–4.0 months (3 month time point); 4.1–8.0 months (6 month time point); 8.1–18.0 months (12 month time point); and 18.1–30.0 months (24 month time point). The linear mixed effects model used all eGFR data from all relevant patients to predict changes from baseline.